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836Percutaneous Mitral
Valve Repair With the
MitraClip System for
Severe Mitral Regurgitation
in Patients With Surgical
Mitral Valve Repair FailureTo the Editor: Surgical mitral valve repair (SMVR) is the preferred
intervention for patients with either symptomatic severe mitral
regurgitation (MR) or asymptomatic severe MR and left ventricular
dysfunction (1). The rate of freedom from severe MR 10 years after
SMVR, however, is reported to be 70% (2), leading to aTable 1 Patient Characteristics, Procedural Details, and Follow-Up Data
Variable Patient #1 Patient #2
Age (yrs) 74 77
Sex Female Female
NYHA functional class (baseline) 3 3
Logistic EuroSCORE (%) 42.9 12.9
STS score (%) 11.4 4.2
Interval between SMVR and PMVR 12 yrs 6.5 yrs
Type of surgical ring Carpentier-
Edwards
Sovering
Miniband
Pre-procedural
Rhythm SR SR
LVEF (%) 30 30
MR etiology Functional Functional
Tethering (involved leaﬂet) Yes (P) Yes (P)
MR jets Central Central
MR grade 3 3
Systolic PAP (mm Hg) 50 50
Mean pressure gradient (mm Hg) 1.8 2.5
Mitral valve area (cm2) 4.3 3.3
Coaptation depth (mm) 9 8
Coaptation length (mm) 5 6
Procedural details
Device success Yes Yes
Number of clips needed 1 1
Device implantation time (min) 55 33
Total ﬂuoroscopy time (min) 27 13
Post-procedural
MR grade 1 1
Mean pressure gradient (mm Hg) 5 3.1
Mitral valve area (cm2) 2.6 1.9
Procedural complications None None
Hospital stay (days) 4 5
Follow-up
Follow-up (months) 31 12
MR grade 1 1
LVEF improvement Yes Yes
NYHA functional class 2 2
A ¼ anterior leaﬂet; AF ¼ atrial ﬁbrillation; EuroSCORE ¼ European System for Cardiac Operative Risk E
NYHA ¼ New York Heart Association; P¼ posterior leaﬂet; PAP¼ pulmonary artery pressure; PMVR¼ per
of Thoracic Surgeons.considerable number of mitral valve reinterventions, which carry
substantial risk, particularly in elderly patients and in those with
signiﬁcant comorbidities.
Percutaneous mitral valve repair (PMVR) with the MitraClip
system (Abbott Laboratories, Abbott Park, Illinois) recently
emerged as a promising therapeutic alternative to SMVR in patients
who are at high risk or are unsuitable for conventional surgery (3).
Because of its reduced invasiveness compared with conventional
surgery, PMVR could as well function as a potential alternative to
reoperation in patients with SMVR failure. Although the feasibility
of transcatheter valve implantation after SMVR failure has already
been reported (4), studies assessing the feasibility and efﬁcacy of
PMVRwith theMitraClip system in this setting are very limited (5).
We report, therefore, our initial experience with MitraClip im-
plantation in patients with SMVR (i.e., annuloplasty) failure.
Between August 2008 and June 2013, a total of 154 consecutive
patients with moderate to severe (grade 3þ) or severe (grade 4þ)
MR determined to be at high surgical risk who underwent PMVR
at our institution were prospectively included in our GRASPPatient #3 Patient #4 Patient #5 Patient #6
79 75 72 72
Female Male Male Female
3 4 2 4
13.6 13.0 15.0 20.1
6.0 4.6 5.0 6.0
5 yrs 10 yrs 8 yrs 7 days
Carpentier-
Edwards
Carpentier-
Edwards
Sovering
Miniband
Cosgrove-
Edwards
SR AF AF SR
35 35 29 45
Functional Functional Functional Functional
Yes (P) Yes (P) Yes (A, P) Yes (A)
Central-medial Central-medial Central Central-lateral
3 4 4 4
35 45 35 60
2.7 4.5 2.6 3.8
3.0 3.7 3.7 3.7
8 10 8 5
4 5 4 3
Yes Yes Yes Yes
1 1 1 1
67 60 75 30
33 28 35 18
1 2 1 1
5 6 4.8 5
2.5 1.5 2.4 1.9
None None None None
2 5 2 NA
12 6 3 NA
3 1 1 NA
No Yes Yes NA
3 2 1 NA
valuation; LVEF ¼ left ventricular ejection fraction; MR ¼ mitral regurgitation; NA ¼ not available;
cutaneous mitral valve repair; SMVR ¼ surgical mitral valve repair; SR¼ sinus rhythm; STS¼ Society
Figure 1 Transesophageal Echocardiography Before and After the Procedure From a Representative Case (Patient #6)
In the long-axis view, mitral regurgitation reduction from severe (A) to trivial (C) is shown, whereas in the 3-dimensional echocardiographic view from the left atrium (LA), the
annuloplasty ring (Cosgrove-Edwards; white arrowheads) is clearly demonstrated in the posterior annulus (B,D) with a double oriﬁce (white asterisk) after MitraClip implan-
tation (D). Ao ¼ aorta; LV ¼ left ventricle.
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Implantation) registry (6). The decision to proceed with PMVR
was discussed by a dedicated heart team, including experienced
clinical and interventional cardiologists, cardiovascular surgeons,
and anesthesiologists. Qualifying inclusion and exclusion criteria
for PMVR, as well as details of the procedure, were previously
reported (3). Throughout the study period, PMVR was performed
in 6 patients (3.9%) with surgical mitral valve annuloplasty failure.
Baseline, procedural, and follow-up characteristics are listed in
Table 1. The median interval between SMVR and PMVR was
8 years (range: 5 to 12 years). One case was performed, however,
7 days after SMVR as a “bailout” procedure for acute surgical
failure. Device success, deﬁned as residual MR grade  2þ after
clip implantation, was achieved in all patients. Post-procedural
MR grade, the mean pressure gradient of the mitral valve
(4.9  0.9 mm Hg), and mitral valve area (2.1  0.4 cm2) were
satisfactory. No cases of procedural death, stroke, myocardial
infarction, or urgent cardiovascular surgery occurred. Patient # 6,
in whom PMVR was performed in the acute phase (i.e., 7 days
after SMVR), died because of multiple-organ failure during the
hospital stay, thus imparting all-cause and cardiovascular mor-
tality rates of 16.7% and 0%, respectively. Follow-up was available
in all remaining 5 patients (median follow-up period 12 months;
range: 3 to 31 months). All patients but one (Patient #3) expe-
rienced improvements in New York Heart Association (NYHA)
functional class compared with baseline and maintenance or
improvement of MR status compared with post-procedural at
follow-up (Table 1).When our ﬁndings are put into perspective with the overall
population from the GRASP registry, the mean age and logistic
European System for Cardiac Operative Risk Evaluation score
were signiﬁcantly higher in patients with versus without prior
SMVR (74.8  2.8 years vs. 71.6  10.2 years, p ¼ 0.041, and
19.6  11.7 years vs. 10.4  10.9 years, p ¼ 0.046, respectively),
whereas no signiﬁcant differences were observed in terms of
baseline NYHA functional class and left ventricular ejection fraction
(37.0  7.3% vs. 36.8  13.2%, p ¼ 0.942). All patients with prior
SMVR underwent successful procedures with the implantation of
only 1 clip, which was signiﬁcantly lower compared with those
without prior SMVR (p ¼ 0.027). No signiﬁcant differences were
documented regarding device implantation and total ﬂuoroscopy
time, as well as length of hospital stay between the groups.
Patients with prior surgical mitral valve annuloplasty have
reduced mitral valve areas due to the previously implanted annu-
loplasty ring; therefore, being able to effectively reduce MR by
implanting only 1 clip (representative images shown in Fig. 1) per
patient in our series was noteworthy, as we could show the effec-
tiveness of the intervention while minimizing concerns regarding
potential secondary increases in pressure gradients. Indeed,
acceptable post-procedural transvalvular mean pressure gradients
and mitral valve areas were demonstrated in all patients (Table 1).
Furthermore, we were able to demonstrate the stability of MR
reduction coupled with improvement in left ventricular ejection
fraction and NYHA functional class in all but in 1 patient over
time. Another important ﬁnding, despite our small number of
patients, was the safety of PMVR in patients with SMVR failure;
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838in fact, notwithstanding the high baseline patient risk proﬁle, no
procedure-related adverse events were documented.
We acknowledge some limitations of our pivotal study. First, the
comparisons between patients with and without prior SMVR should
be interpreted with caution, because they were not pre-deﬁned in
our initial protocol; nevertheless, they help in settling our patients’
high-risk clinical status while reassuring the feasibility and original
signs of effectiveness of the intervention performed. Second, larger
series and longer term follow-up are warranted to conﬁrm our initial
ﬁndings in this highly selected population. Finally, determining the
most appropriate therapy (i.e., PMVR or surgical reoperation) for
patients with SMVR failure warrants future investigation.
In conclusion, we were able to demonstrate in a preliminary
experience the safety and efﬁcacy of PMVR with the MitraClip
therapy in patients with surgical mitral valve annuloplasty failure.
The promising results demonstrated herewith, therefore, open a
new avenue for further investigation of the role of MitraClip im-
plantation in this complex clinical scenario.*Carmelo Grasso, MDy
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Cardiol 2013;111:1482–7.Letter to the EditorEndpoints for Diuresis
Are We There Yet?
Diuretics and relief of congestion remain the mainstay of therapy in
patients hospitalized with heart failure (HF), regardless of ejection
fraction. However, limited data and established practice guidelines
are available to guide clinicians in the duration and intensity of
inpatient diuresis. In a recent issue of the Journal, van der Meer et al.
(1) add to the growing body of published data indicating that
changes in certain parameters during hospital stay, including renal
function (2), body weight (3), and intravascular volume (4), might
predict post-discharge clinical course. In addition to deﬁning the
ideal surrogate marker(s) to reﬂect clinical euvolemia, future initia-
tives in this area should address the optimal method of decongestion
and the compartment of desired ﬂuid removal (intravascular, extra-
vascular, and so forth). Subpopulations such as patients with chronic
kidney disease, advanced HF, predominant right-sided HF, andHF
with preserved ejection fraction likely warrant special consideration.
Matching the right marker of decongestion with the right patient
population will be an important objective of future studies.
Overall length of stay inHFhas trended down, despite persistently
high rates of post-discharge outcomes (5). This might reﬂect inad-
equate congestion, because approximately 50% of HF patients
lose <2 kg during hospital stay (6). Early readmissions might be
related to hemodynamic perturbations rather than progression ofHF
and thus might be at least partially responsive to aggressive volume
management. Comparative strategies for various metric-guided ap-
proaches to decongestion should be prospectively assessed to opti-
mize post-discharge outcomes in HF. The tremendous economic
and clinical burden of HF demands a more nuanced, systematic, and
standardized approach to the management of congestion.Muthiah Vaduganathan, MD, MPH
Stephen J. Greene, MD
Javed Butler, MD, MPH
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